Art. -Nr.: HY-13832

Atovaquone

(Synonyms: Atavaquone)

4 Cited Publications

Kundenbewertung

Based on 4 publication(s) in Google Scholar

Atovaquone (Atavaquone) is a potent, selective and orally active inhibitor of the parasite’s mitochondrial cytochrome bc1 complex. Atovaquone is against human and P. falciparum cytochrome bc1 activity with IC₅₀ values of 460 nM and 2.0 nM, respectively. Atovaquone is an antimalarial agent and has the potential for the investigation of neumocystis pneumonia, toxoplasmosis, malaria, and babesia.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 99.75%
CAS. Nr.: 95233-18-4
Formel: C₂₂H₁₉ClO₃
Molecular Weight:366.84

Speicherung:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year

Atovaquone Chemical Structure

CAS. Nr.: 95233-18-4

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
- Clinical Trial
Chemical Information
Publications (4)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

IC₅₀ & Target

Plasmodium

Alle Parasite Isoform-spezifische Produkte anzeigen :

Alle Cytochrome P450 Isoform-spezifische Produkte anzeigen :

Alle Antibiotic Isoform-spezifische Produkte anzeigen :

Cellular Effect

Cell Line	Type	Value	Description	References
BJ	EC₅₀	>21.5 μM Compound: 4	Cytotoxicity against human BJ cells after 72 hrs by luminescence analysis Cytotoxicity against human BJ cells after 72 hrs by luminescence analysis	[PMID: 22435599]
DU-145	IC₅₀	29.3 μM Compound: Atovaquone	Growth inhibition of human DU145 cells after 72 hrs by MTT assay Growth inhibition of human DU145 cells after 72 hrs by MTT assay	[PMID: 19632833]
HEK293	IC₅₀	0.41 μM Compound: Atovaquone	Inhibition of human cytochrome bc1 complex derived from HEK293 cell mitochondria using 50 uM decylubiquinol as substrate Inhibition of human cytochrome bc1 complex derived from HEK293 cell mitochondria using 50 uM decylubiquinol as substrate	[PMID: 24720377]
HEK293	IC₅₀	2 nM Compound: 46	Inhibition of Plasmodium falciparum cytochrome bc1 expressed in HEK293 cells by spectrophotometric analysis Inhibition of Plasmodium falciparum cytochrome bc1 expressed in HEK293 cells by spectrophotometric analysis	[PMID: 26791529]
HEK293	IC₅₀	>10000 nM Compound: 46	Inhibition of Plasmodium falciparum NDH2 expressed in HEK293 cells by spectrophotometric analysis Inhibition of Plasmodium falciparum NDH2 expressed in HEK293 cells by spectrophotometric analysis	[PMID: 26791529]
HEK293	CC₅₀	49 nM Compound: 18	Cytotoxicity against HEK293 cells incubated for 48 hrs by MTT assay Cytotoxicity against HEK293 cells incubated for 48 hrs by MTT assay	[PMID: 33333397]
Hepatocyte	IC₅₀	57 nM Compound: Atovaquone	Antimicrobial activity against Plasmodium yoelii 265 liver infected in mammalian hepatocytes after 48 hrs Antimicrobial activity against Plasmodium yoelii 265 liver infected in mammalian hepatocytes after 48 hrs	[PMID: 18212104]
HepG2	EC₅₀	>21.5 μM Compound: 4	Cytotoxicity against human HepG2 cells after 72 hrs by luminescence analysis Cytotoxicity against human HepG2 cells after 72 hrs by luminescence analysis	[PMID: 22435599]
HepG2	IC₅₀	>10 μM Compound: 92125513	HARVARD: Cytotoxicity in HepG2 cell line HARVARD: Cytotoxicity in HepG2 cell line	[PMID: 22586124]
HepG2	IC₅₀	0.0003 μM Compound: 92125513	HARVARD: Inhibition of liver stage Plasmodium berghei infection in HepG2 cells HARVARD: Inhibition of liver stage Plasmodium berghei infection in HepG2 cells	[PMID: 22586124]
HepG2	IC₅₀	0.3 nM Compound: 92125513	HARVARD: Inhibition of liver stage Plasmodium berghei infection in HepG2 cells HARVARD: Inhibition of liver stage Plasmodium berghei infection in HepG2 cells	[PMID: 22586124]
HepG2	IC₅₀	<1 μM Compound: Atovaquone	Antimalarial activity against sporozoite stage of Plasmodium yoelii assessed as invasion of human HepG2 cells expressing CD81 incubated for 2 hrs prior to inoculation measured after 1 hr by immunofluorescence assay in presence of penicillin/streptomycin Antimalarial activity against sporozoite stage of Plasmodium yoelii assessed as invasion of human HepG2 cells expressing CD81 incubated for 2 hrs prior to inoculation measured after 1 hr by immunofluorescence assay in presence of penicillin/streptomycin	[PMID: 23927658]
HepG2	EC₅₀	0.5 nM Compound: 37, Atovaquone	Antimicrobial activity against Plasmodium berghei sporozoites infected in 12 hrs compound pretreated human HepG2 cells assessed as reduction in viability of exoerythrocytic forms measured after 48 hrs of incubation by luciferase bioluminescence assay Antimicrobial activity against Plasmodium berghei sporozoites infected in 12 hrs compound pretreated human HepG2 cells assessed as reduction in viability of exoerythrocytic forms measured after 48 hrs of incubation by luciferase bioluminescence assay	[PMID: 24641010]
HepG2	IC₅₀	>10 μM Compound: Atovaquone	Cytotoxicity against human HepG2 cells after 24 hrs incubation by Alamar Blue assay Cytotoxicity against human HepG2 cells after 24 hrs incubation by Alamar Blue assay	[PMID: 24720377]
HepG2	IC₅₀	0.00016 μM Compound: Atovaquone	Antimalarial activity against exo-erythrocytic form of Plasmodium berghei infected in human HepG2 cells after 48 hrs Antimalarial activity against exo-erythrocytic form of Plasmodium berghei infected in human HepG2 cells after 48 hrs	[PMID: 24904967]
HepG2	IC₅₀	0.16 nM Compound: Atovaquone	Antimalarial activity against exo-erythrocytic form of Plasmodium berghei infected in human HepG2 cells after 48 hrs Antimalarial activity against exo-erythrocytic form of Plasmodium berghei infected in human HepG2 cells after 48 hrs	[PMID: 24904967]
HepG2	CC₅₀	>15.6 μM Compound: Atovaquone	Cytotoxicity against human HepG2 cells assessed as cell viability after 72 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as cell viability after 72 hrs by MTT assay	[PMID: 25791675]
HepG2	CC₅₀	9.5 μM Compound: Atovaquone	Cytotoxicity against human HepG2 cells expressing CD81 assessed as cell viability after 72 hrs by CellTiter-glo assay Cytotoxicity against human HepG2 cells expressing CD81 assessed as cell viability after 72 hrs by CellTiter-glo assay	[PMID: 25791675]
HepG2	IC₅₀	9 nM Compound: Atovaquone	Antiplasmodial activity against liver stage of Plasmodium yoelii 17X NL sporozoites infected in human HepG2 cells expressing CD81 after 48 hrs by DAPI staining-based immunofluorescence analysis Antiplasmodial activity against liver stage of Plasmodium yoelii 17X NL sporozoites infected in human HepG2 cells expressing CD81 after 48 hrs by DAPI staining-based immunofluorescence analysis	[PMID: 25791675]
HepG2	IC₅₀	22 nM Compound: ATQ	Antimalarial activity against sporozoite stage of Plasmodium berghei yoelii infected in human HepG2 cells Antimalarial activity against sporozoite stage of Plasmodium berghei yoelii infected in human HepG2 cells	[PMID: 26640981]
HepG2	CC₅₀	>15.6 μM Compound: Atovaquone	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 27654395]
HepG2	CC₅₀	>40 μM Compound: 2	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 24 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 24 hrs by MTT assay	[PMID: 29324340]
HepG2	IC₅₀	23160 nM Compound: ATV	Cytotoxicity against human HepG2 cells measured after 24 to 36 hrs by resazurin dye based fluorescence assay Cytotoxicity against human HepG2 cells measured after 24 to 36 hrs by resazurin dye based fluorescence assay	[PMID: 30852885]
HepG2	IC₅₀	23160 nM Compound: ATV	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay	[PMID: 32390431]
HepG2	CC₅₀	>30 μM Compound: ATQ	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by CellTiter-Glo assay Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by CellTiter-Glo assay	[PMID: 33620219]
HepG2	IC₅₀	8496 nM Compound: ATV	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability measured for 48 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as reduction in cell viability measured for 48 hrs by MTT assay	[PMID: 34111350]
HepG2	CC₅₀	>15.6 μM Compound: Atovaquone	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay	[PMID: 34364164]
HFF	IC₅₀	0.28 μM Compound: Atovaquone	Inhibitory concentration against the growth of Toxoplasma gondii overexpressing FPPS enzyme in human foreskin fibroblast monolayer cells; (control = 0.29 uM) Inhibitory concentration against the growth of Toxoplasma gondii overexpressing FPPS enzyme in human foreskin fibroblast monolayer cells; (control = 0.29 uM)	[PMID: 15857119]
HFF	IC₅₀	0.29 μM Compound: Atovaquone	Antiparasitic activity against Toxoplasma gondii tachyzoites m2m3 infected HFF cells Antiparasitic activity against Toxoplasma gondii tachyzoites m2m3 infected HFF cells	[PMID: 17643987]
Huh-7	IC₅₀	0.37 nM Compound: ATV	Antiplasmodial activity against liver stage Plasmodium berghei infected in human HuH7 cells co-expressing GFP-Luccon treated for 1 hr prior to infection followed by 24 hrs after compound washout measured after 48 hrs post-infection by Alamar Blue assay Antiplasmodial activity against liver stage Plasmodium berghei infected in human HuH7 cells co-expressing GFP-Luccon treated for 1 hr prior to infection followed by 24 hrs after compound washout measured after 48 hrs post-infection by Alamar Blue assay	[PMID: 23701465]
Huh-7	IC₅₀	0.0018 μM Compound: ATQ	Antiplasmodial activity against liver-stage of Plasmodium berghei expressing firefly luciferase infected in human Huh-7 cells after 48 hrs by bioluminescence assay Antiplasmodial activity against liver-stage of Plasmodium berghei expressing firefly luciferase infected in human Huh-7 cells after 48 hrs by bioluminescence assay	[PMID: 26142491]
J774	EC₅₀	28.3 μM Compound: ATO	Cytotoxicity against mouse J774 cells Cytotoxicity against mouse J774 cells	[PMID: 27291102]
J774	EC₅₀	28 μM Compound: ATO	Cytotoxicity against mouse J774 cells after 72 hrs by CellTiter-96 aqueous one solution cell proliferation assay Cytotoxicity against mouse J774 cells after 72 hrs by CellTiter-96 aqueous one solution cell proliferation assay	[PMID: 29215279]
KB	IC₅₀	>5 μg/mL Compound: atovaquone	Cytotoxicity against human KB cells assessed as [3H]hypoxanthine incorporation after 48 hrs Cytotoxicity against human KB cells assessed as [3H]hypoxanthine incorporation after 48 hrs	[PMID: 19199790]
MCF7	IC₅₀	1 μM Compound: Atovaquone	Inhibition of mammosphere formation in human MCF7 cells incubated for 5 days Inhibition of mammosphere formation in human MCF7 cells incubated for 5 days	[PMID: 33103432]
MRC5	IC₅₀	0.03 mg/L Compound: Atovaquone	Antimicrobial activity against Toxoplasma gondii isolate GRE-1995-MAE infected in human MRC-5 cells after 72 hrs by ELISA Antimicrobial activity against Toxoplasma gondii isolate GRE-1995-MAE infected in human MRC-5 cells after 72 hrs by ELISA	[PMID: 18212105]
MRC5	IC₅₀	0.03 mg/L Compound: Atovaquone	Antimicrobial activity against Toxoplasma gondii NED infected in human MRC-5 cells after 72 hrs by ELISA Antimicrobial activity against Toxoplasma gondii NED infected in human MRC-5 cells after 72 hrs by ELISA	[PMID: 18212105]
MRC5	IC₅₀	0.04 mg/L Compound: Atovaquone	Antimicrobial activity against Toxoplasma gondii isolate GUY-2003-MEL harboring DHPS Ex2, E474D/Ex4, R560K/Ex5, 580 sil Gly/ A597E/627 sil Glu mutant gene and DHFR Ex2, 145 sil Val mutant gene infected in human MRC-5 cells after 72 hrs by ELISA Antimicrobial activity against Toxoplasma gondii isolate GUY-2003-MEL harboring DHPS Ex2, E474D/Ex4, R560K/Ex5, 580 sil Gly/ A597E/627 sil Glu mutant gene and DHFR Ex2, 145 sil Val mutant gene infected in human MRC-5 cells after 72 hrs by ELISA	[PMID: 18212105]
MRC5	IC₅₀	0.04 mg/L Compound: Atovaquone	Antimicrobial activity against Toxoplasma gondii isolate RMS-1994-LEF harboring DHPS Ex2, E474D/Ex4, R560K/Ex5, 580 sil Gly; A597E/627 sil Glu mutant gene and DHFR Ex3, 204 sil Ala mutant gene infected in human MRC-5 cells after 72 hrs by ELISA Antimicrobial activity against Toxoplasma gondii isolate RMS-1994-LEF harboring DHPS Ex2, E474D/Ex4, R560K/Ex5, 580 sil Gly; A597E/627 sil Glu mutant gene and DHFR Ex3, 204 sil Ala mutant gene infected in human MRC-5 cells after 72 hrs by ELISA	[PMID: 18212105]
MRC5	IC₅₀	0.04 mg/L Compound: Atovaquone	Antimicrobial activity against Toxoplasma gondii isolate RMS-2005-HAG infected in human MRC-5 cells after 72 hrs by ELISA Antimicrobial activity against Toxoplasma gondii isolate RMS-2005-HAG infected in human MRC-5 cells after 72 hrs by ELISA	[PMID: 18212105]
MRC5	IC₅₀	0.05 mg/L Compound: Atovaquone	Antimicrobial activity against Toxoplasma gondii isolate GRE-1998-TRA infected in human MRC-5 cells after 72 hrs by ELISA Antimicrobial activity against Toxoplasma gondii isolate GRE-1998-TRA infected in human MRC-5 cells after 72 hrs by ELISA	[PMID: 18212105]
MRC5	IC₅₀	0.05 mg/L Compound: Atovaquone	Antimicrobial activity against Toxoplasma gondii ME49 infected in human MRC-5 cells infected in human MRC-5 cells after 72 hrs by ELISA Antimicrobial activity against Toxoplasma gondii ME49 infected in human MRC-5 cells infected in human MRC-5 cells after 72 hrs by ELISA	[PMID: 18212105]
MRC5	IC₅₀	0.05 mg/L Compound: Atovaquone	Antimicrobial activity against Toxoplasma gondii RH harboring DHPS Ex2, E474D/Ex4, R560K/Ex5, 580 sil Gly; A597E/627 sil Glu mutant gene and DHFR Ex3, 156 sil Leu mutant gene infected in human MRC-5 cells after 72 hrs by ELISA Antimicrobial activity against Toxoplasma gondii RH harboring DHPS Ex2, E474D/Ex4, R560K/Ex5, 580 sil Gly; A597E/627 sil Glu mutant gene and DHFR Ex3, 156 sil Leu mutant gene infected in human MRC-5 cells after 72 hrs by ELISA	[PMID: 18212105]
MRC5	IC₅₀	0.06 mg/L Compound: Atovaquone	Antimicrobial activity against Toxoplasma gondii isolate PSP-2005-MUP infected in human MRC-5 cells after 72 hrs by ELISA Antimicrobial activity against Toxoplasma gondii isolate PSP-2005-MUP infected in human MRC-5 cells after 72 hrs by ELISA	[PMID: 18212105]
MRC5	IC₅₀	0.06 mg/L Compound: Atovaquone	Antimicrobial activity against Toxoplasma gondii isolate RMS-2001-MAU infected in human MRC-5 cells after 72 hrs by ELISA Antimicrobial activity against Toxoplasma gondii isolate RMS-2001-MAU infected in human MRC-5 cells after 72 hrs by ELISA	[PMID: 18212105]
MRC5	IC₅₀	0.07 mg/L Compound: Atovaquone	Antimicrobial activity against Toxoplasma gondii ENT harboring DHPS Ex2, E474D/Ex3, 156 sil Leu/Ex4, R560K/Ex5, 580 sil Gly/A597E/627 sil Glu mutant gene and DHFR Ex3, 156 sil Leu mutant gene infected in human MRC-5 cells after 72 hrs by ELISA Antimicrobial activity against Toxoplasma gondii ENT harboring DHPS Ex2, E474D/Ex3, 156 sil Leu/Ex4, R560K/Ex5, 580 sil Gly/A597E/627 sil Glu mutant gene and DHFR Ex3, 156 sil Leu mutant gene infected in human MRC-5 cells after 72 hrs by ELISA	[PMID: 18212105]
MRC5	IC₅₀	0.07 mg/L Compound: Atovaquone	Antimicrobial activity against Toxoplasma gondii isolate TOU-1998-TRI infected in human MRC-5 cells after 72 hrs by ELISA Antimicrobial activity against Toxoplasma gondii isolate TOU-1998-TRI infected in human MRC-5 cells after 72 hrs by ELISA	[PMID: 18212105]
MRC5	IC₅₀	0.07 mg/L Compound: Atovaquone	Antimicrobial activity against Toxoplasma gondii isolate TRS-2004-REV infected in human MRC-5 cells after 72 hrs by ELISA Antimicrobial activity against Toxoplasma gondii isolate TRS-2004-REV infected in human MRC-5 cells after 72 hrs by ELISA	[PMID: 18212105]
MRC5	IC₅₀	0.08 mg/L Compound: Atovaquone	Antimicrobial activity against Toxoplasma gondii isolate RMS-2003-DJO infected in human MRC-5 cells after 72 hrs by ELISA Antimicrobial activity against Toxoplasma gondii isolate RMS-2003-DJO infected in human MRC-5 cells after 72 hrs by ELISA	[PMID: 18212105]
MRC5	IC₅₀	0.1 mg/L Compound: Atovaquone	Antimicrobial activity against Toxoplasma gondii B1 harboring DHPS Ex2, E474D/Ex4, R560K/Ex5, 580 sil Gly/ A597E/627 sil Glu mutant gene and DHFR Ex3, 156 sil Leu mutant gene infected in human MRC-5 cells after 72 hrs by ELISA Antimicrobial activity against Toxoplasma gondii B1 harboring DHPS Ex2, E474D/Ex4, R560K/Ex5, 580 sil Gly/ A597E/627 sil Glu mutant gene and DHFR Ex3, 156 sil Leu mutant gene infected in human MRC-5 cells after 72 hrs by ELISA	[PMID: 18212105]
MRC5	IC₅₀	0.11 mg/L Compound: Atovaquone	Antimicrobial activity against Toxoplasma gondii isolate RMS-1995-ABE harboring DHPS Ex5, A587V mutant gene infected in human MRC-5 cells after 72 hrs by ELISA Antimicrobial activity against Toxoplasma gondii isolate RMS-1995-ABE harboring DHPS Ex5, A587V mutant gene infected in human MRC-5 cells after 72 hrs by ELISA	[PMID: 18212105]
Raji	EC₅₀	>21.5 μM Compound: 4	Cytotoxicity against human Raji cells after 72 hrs by luminescence analysis Cytotoxicity against human Raji cells after 72 hrs by luminescence analysis	[PMID: 22435599]
Vero	CC₅₀	0.5 μM Compound: ATQ	Cytotoxicity against African green monkey Vero cells assessed as inhibition of cell proliferation Cytotoxicity against African green monkey Vero cells assessed as inhibition of cell proliferation	[PMID: 33636304]
Vero	CC₅₀	9.5 μM Compound: ATO	Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability measured after 3 days by MTT assay Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability measured after 3 days by MTT assay	[PMID: 37336083]

In Vitro

Atovaquone targets to the Q_o site of the Plasmodium cytochrome bc1 complex of the mitochondrial electron transport chain^[1].
Atovaquone is against the development in the mosquito from gamete production, through fertilization, zygote formation and finally, to the development of the mature ookinete, and demonstrates an IC₅₀ of 67 nM providing further evidence of the transmission blocking potential of this molecule^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Atovaquone (oral administration; 100 mg/kg; once daily) is against survival rates of mice, mice treated orally died within 22 days after discontinuation of sulfadiazine,while the control group died at day 14^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

ICSBP^−/− mice infected with 10 cysts of the ME49 strain of T. gondii^[2]
Dosage:

100 mg/kg
Administration:

Oral administration
Result:

Improved mice survival rate to 22 days compared to vehicle.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

CAS. Nr. 95233-18-4
Appearance Solid
Molecular Weight 366.84
Formel C₂₂H₁₉ClO₃
Color Light yellow to yellow
SMILES

O=C1C([C@H]2CC[C@H](C3=CC=C(Cl)C=C3)CC2)=C(O)C(C4=C1C=CC=C4)=O
Synonyms

Atavaquone
Versand

Room temperature in continental US; may vary elsewhere.

Speicherung

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Publications (4)

All IF

Sort by:

Journal Impact Factor

Free Radic Biol Med

Downregulation of TDP43 by atovaquone inhibits oxidative phosphorylation and enhances sensitivity of triple-negative breast cancer to EGFR-TKIs. [Abstract]

2026 Mar 19:250:64-79. PMID: 41862009
Biomed J

Repurposing old drugs as antiviral agents for coronaviruses. [Abstract]

2020 Aug;43(4):368-374. PMID: 32563698

Atovaquone purchased from MedChemExpress. Usage Cited in: Biomed J. 2020 Aug;43(4):368-374. [Abstract]

Atovaquone (10 μM; 30 min) treatment effectively reduced nucleocapsid protein and inhibited the replication of HCoV-OC43 in HCT-8 cells.
ACS Omega

Identification of New Modulators and Inhibitors of Palmitoyl-Protein Thioesterase 1 for CLN1 Batten Disease and Cancer. [Abstract]

2024 Feb 28;9(10):11870-11882. PMID: 38496939
ChemMedChem

Synthesis and Characterization of DHODH Inhibitors Based on the Vidofludimus Scaffold with Pronounced Anti-SARS-CoV-2 Activity. [Abstract]

2024 Jun 18:e202400292. PMID: 38887198

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 8.33 mg/mL (22.71 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.7260 mL

13.6299 mL

27.2598 mL

5 mM

0.5452 mL

2.7260 mL

5.4520 mL

10 mM

0.2726 mL

1.3630 mL

2.7260 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: 0.83 mg/mL (2.26 mM); Suspended solution; Need ultrasonic

This protocol yields a suspended solution of 0.83 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (8.3 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 0.83 mg/mL (2.26 mM); Clear solution

This protocol yields a clear solution of ≥ 0.83 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (8.3 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (285 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Nilsen A, et al. Quinolone-3-diarylethers: a new class of antimalarial drug.Sci Transl Med. 2013 Mar 20;5(177):177ra37. [Content Brief]

[2]. Schöler N, et al. Atovaquone nanosuspensions show excellent therapeutic effect in a new murine model of reactivated toxoplasmosis.Antimicrob Agents Chemother. 2001 Jun;45(6):1771-9. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.7260 mL	13.6299 mL	27.2598 mL	68.1496 mL
	5 mM	0.5452 mL	2.7260 mL	5.4520 mL	13.6299 mL
	10 mM	0.2726 mL	1.3630 mL	2.7260 mL	6.8150 mL
	15 mM	0.1817 mL	0.9087 mL	1.8173 mL	4.5433 mL
	20 mM	0.1363 mL	0.6815 mL	1.3630 mL	3.4075 mL

Keywords

Atovaquone

4 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

Atovaquone

Anti-Infection Compound Library

Metabolism/Protease Compound Library

FDA-Approved Drug Library

Anti-Cancer Compound Library

Anti-Aging Compound Library

Drug Repurposing Compound Library

Antioxidant Compound Library

Oxygen Sensing Compound Library

Antibacterial Compound Library

Orally Active Compound Library

FDA Approved & Pharmacopeial Drug Library

Antibiotics Library

Drug-Induced Liver Injury (DILI) Compound Library

Antiparasitic Compound library

Mitochondria-Targeted Compound Library

Rare Diseases Drug Library

FDA-Approved Anticancer Drug Library

Human Metabolite Library

Off-patent Drug Library

Metabolic Enzyme Compound Library

Mitochondrial Toxicity Compound Library

Highly Selective Inhibitors Library

Multi-Target Compound Library

Radioprotector Library

Bioactive Compound Library Max

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

FDA-Approved Drug Library Mini

Bioactive Compound Library

High-Throughput Bioactive Compound Library

Mass Spectrometry Human Metabolite Library

Publications Citing Use of MedChemExpress (MCE) Atovaquone

Alle Parasite Isoform-spezifische Produkte anzeigen

Alle Cytochrome P450 Isoform-spezifische Produkte anzeigen

Alle Antibiotic Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (4)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

Atovaquone Related Classifications

HY-13832 Related Classifications